The Role of Adjuvant and Neoadjuvant Therapy in Melanoma: Why Use Adjuvant If There Are Neoadjuvant Data?

Drs Sapna Patel and Matteo Carlino dive into the data and consider the current and future roles of adjuvant and neoadjuvant therapy.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989030). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Malignant Melanoma https://emedicine.medscape.com/article/280245-overview

Neoadjuvant-adjuvant or Adjuvant-only Pembrolizumab in Advanced Melanoma https://www.nejm.org/doi/10.1056/NEJMoa2211437

Malignant Melanoma Staging https://emedicine.medscape.com/article/2007147-overview

Pembrolizumab (Rx) https://reference.medscape.com/drug/keytruda-pembrolizumab-999962

Nivolumab (Rx) https://reference.medscape.com/drug/opdivo-nivolumab-999989

Five-year Analysis of Adjuvant Dabrafenib Plus Trametinib in Stage III Melanoma https://www.nejm.org/doi/10.1056/NEJMoa2005493

Effectiveness of Adjuvant Pembrolizumab vs High-dose Interferon or Ipilimumab for Quality-of-life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/36416836/

TNM Classification of Malignant Tumours, 8th Edition https://www.wiley.com/en-gb/TNM+Classification+of+Malignant+Tumours%2C+8th+Edition-p-9781119263579

RECIST 1.1-Update and Clarification: From the RECIST Committee https://pubmed.ncbi.nlm.nih.gov/27189322/

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA) https://clinicaltrials.gov/ct2/show/NCT04949113

Ipilimumab (Rx) https://reference.medscape.com/drug/yervoy-ipilimumab-999636

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-risk Melanoma (KEYNOTE-942) https://clinicaltrials.gov/ct2/show/NCT03897881

Adjuvant BRAF-MEK Inhibitors Versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-matched Outcome Analysis https://pubmed.ncbi.nlm.nih.gov/36672358/

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134 https://pubmed.ncbi.nlm.nih.gov/36166727/